J. Brian Xu, M.D., Ph.D., D.A.B.T., Joins Bergeson & Campbell, P.C. and The Acta Group as Toxicologist

Bergeson & Campbell, P.C. (B&C^®) and The Acta Group (Acta) are pleased to announce the addition of Brian Xu, Ph.D., to our firms. Dr. Xu, a board-certified toxicologist and medical doctor, will assist clients in developing and managing international projects involving U.S. Food and Drug Administration (FDA) and U.S. Environmental Protection Agency (EPA) regulated consumer products, pharmaceuticals, cosmetics, industrial and specialty chemicals, agrochemicals, and antimicrobials. Dr. Xu holds an M.D. in pathology, a Ph.D. in pharmacology and toxicology, and has over 15 years of industry experience as a senior toxicologist and scientist at companies such as Ashland, Inc., Schering-Plough, and Merck.

Lynn L. Bergeson, Managing Partner of B&C and President of Acta, stated: “We are delighted to have Dr. Brian Xu join our scientific staff. His significant experience with U.S., Chinese, and other global chemical control and regulatory systems will be a tremendous resource to our clients doing business around the world, and he will help us provide a seamless interface among our Acta China, Acta EU, and Acta U.S. services.”

Dr. Xu began his scientific career at the Chinese Academy of Medical Sciences as a physician at the Cancer Institute and Hospital in Beijing, China, specializing in cancer pathology. He moved to the U.S. in 1991 to continue his education at George Washington University for his doctorate, from whence he proceeded to Yale, where he was a Post-doctoral Fellow in Pharmacology. His professional career has included time at Merck as a Senior Research Biologist and core member of the gene expression technology working group; Schering-Plough, where he was Principal Scientist and Toxicologist in the Department of Drug Safety and Metabolism; and Enzon Pharmaceuticals, where he was Director of Toxicology and Preclinical Pharmacokinetics. Dr. Xu is fluent in English and Mandarin Chinese.